Judge: Elan's J&J deal breached Tysabri partnership

Judge Deborah Batts works fast. In Manhattan federal court yesterday, Batts slapped down Elan's request for an injunction against Biogen Idec, ruling instead that Elan had breached the two companies'

Teva to cut 315 in Irish plant wind-down

Half of Teva Pharmaceutical's workers at a Waterford, Ireland, plant are getting the axe. In the second plant-layoff announcement this week, the Israeli generics maker told workers that 315 jobs will

FDA blesses Shire's latest ADHD med

Shire got the FDA nod for childhood and adolescent use of its extended-release drug Intuniv, the first selective alpha-2A receptor agonist for treatment of ADHD. Report

Biogen, Elan meet in court today

Biogen Idec and Elan are squaring off in court today, a week earlier than expected. Judge Deborah Batts ordered that the first hearing be moved up, and so we could have closure on the case as soon as

Erbitux looks for narrower lung-cancer use

Germany's Merck KGaA hasn't given up on Erbitux for lung cancer. It's sifting clinical data to identify patient subgroups that benefit most from the treatment, the company's pharma chief told

It's jury time in Fosamax jaw-injury case

Both plaintiff and defense have presented their arguments over Merck's Fosamax and its possible links to jawbone death. Now it's up to the jury to decide. And what those 12 people will decide is

Pfizer's $2.3B promise to behave

Back in January, Pfizer set aside $2.3 billion to settle a Justice Department investigation. Word was that it dealt with improper Bextra marketing. But the reality is that, while Bextra infractions

At $2.6B, is Sepracor the best buy for Dainippon?

Another Japanese pharma has snapped up a U.S. drugmaker. This time, it's Dainippon Sumitomo Pharma, which will pay $2.6 billion for Sepracor mainly to get access to the latter's sales network.

Cancer drugs rising to top of sales pyramid

Emerging markets is just one promised land for Big Pharma these days. The other one? Cancer drugs. Because it can be a terminal illness, patients want their oncology meds at any cost, even if the

FDA panel wants new trial for Genzyme med

More bad news for Genzyme: Its leukemia drug Clolar probably won't get a new indication for adults anytime soon. An FDA advisory panel was less than impressed with the company's data supporting

Did Lexapro's success depend on doc payments?

For a behind-the-curtain look at Forest Laboratories' efforts to promote the antidepressant Lexapro, look no further than a marketing plan obtained by a Congressional committee. The 88 pages,

Pfizer eyes Brazil's Neo Quimica for $525M deal

Is Pfizer on the verge of beefing up its presence in Brazil? A Sao Paulo newspaper reports that buyout talks between the drugmaker and Brazilian generics firm Neo Quimica are about to bear fruit.

Five biotech and pharma stocks to watch

FiercePharma's sister publication FierceBiotech asked prominent market analysts to weigh in on major biopharma milestones on the near horizon. So Dr. Simos Simeonidis, the senior biotech analyst for

Middlebrook Pharma pares sales force

Middlebrook Pharma announced Tuesday it had cut its workforce by 100--paring its corporate staff by 20 percent and its sales force by 25 percent. After about $5 million in severance, the staff

Post-ESC, analyst chops Effient forecast

All the blood-thinner action at the European Society of Cardiology meeting has heads spinning. And no one's heads are spinning faster than those at Eli Lilly. The company finally ushered its new

Who will serve on new Merck's front lines?

The big Merck headlines overlooked some of the most important news: The folks taking nitty-gritty jobs at the post-merger company. Here's a primer. Report

'No proof' for combo cholesterol meds

In a blow to combo cholesterol pills, researchers found that there's no proof that two cholesterol drugs are better than high doses of one. The researchers analyzed 102 studies, finding little

Four reform scenarios, four pharma outcomes

Worst-case scenario types, listen up: If U.S. healthcare reform yields a national health plan that offers little patient choice on drugs, then pharma companies would be in a world of hurt. A world in

Takeda tops in marketing to PBMs, HMOs

Drugmakers are spending more time on lobbying these days ... and not just politicians. Of necessity, pharma has focused more of its marketing efforts not on the docs that prescribe the drugs, but

EMEA tags new troubles at Genzyme plant

Genzyme EVP Sandra Poole said her plant at Allston Landing was ready for the inspectors. Well, maybe not quite ready. When European regulators made their visit, they identified one "major" deficiency